MDRNA
Among the firms exploring areas outside of their core RNAi drug focus are Alnylam Pharmaceuticals, Marina Biotech, and RXi Pharmaceuticals.
MDRNA, now known as Marina Biotech, plans a 1-for-4 reverse stock split, which will enable it to have enough authorized shares to consummate the acquisition of Cequent.
Rosetta Genomics top executive said this week that the firm expects to forge at least one strategic partnership by year end, although he did not specify whether it would be around its diagnostics, drug research biomarker, or therapeutics efforts.
Rosetta Genomics said that its chief commercialization officer would resign as the company settles into its latest change in corporate direction. But the company is not the only player in the RNAi/microRNA space to experience changes to its management lineup.
"We've established the intellectual property portfolio and basis to be an integrated personalized medicine company focused in nucleic acid therapeutics and diagnostics," President and CEO Michael French told Gene Silencing News.
Jun 9, 2010
MDRNA Licenses Technology From RiboTask
May 20, 2010
May 6, 2010
Apr 22, 2010
Apr 8, 2010
Apr 8, 2010
Apr 1, 2010
Feb 11, 2010
Jan 28, 2010
Jan 14, 2010
Dec 31, 2009
Dec 31, 2009
MDRNA Closes $1M Bridge Loan
Premium
Dec 17, 2009
Dec 3, 2009
Nov 12, 2009
Oct 8, 2009